What’s the current market cap for McKesson stock?

McKesson (MCK) has a market cap of $89B as of June 03, 2026.

What is the P/E ratio for McKesson stock?

The price to earnings (P/E) ratio for McKesson (MCK) stock is 19.2 as of June 03, 2026.

Does McKesson stock pay dividends?

Yes, the McKesson (MCK) stock pays dividends to shareholders. As of June 03, 2026, the dividend rate is $3.17 and the yield is 0.45%. McKesson has a payout ratio of 8% on a trailing twelve-month basis.

When is the next McKesson dividend payment date?

The next McKesson (MCK) dividend payment is scheduled for July 01, 2026.

What is the beta indicator for McKesson?

McKesson (MCK) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy McKesson stock | $MCK Share Price

About McKesson

McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Ticker

$MCK

Sector

Health

Primary listing

NYSE

Employees

42,300

Headquarters

Irving, United States

Website

www.mckesson.com

McKesson Metrics

BasicAdvanced

$89bn

19.20

$38.38

0.36

$3.17

0.45%

What the Analysts think about McKesson

Analyst ratings (Buy, Hold, Sell) for McKesson stock.

Bulls say / Bears say

McKesson raised its fiscal 2026 adjusted EPS outlook to $38.80–39.20 and surpassed Q3 revenue and EPS estimates, posting revenue of $106.16 billion and adjusted EPS of $9.34 per share (Reuters).

North American pharmaceutical distribution sales grew 9% year-on-year to $88.3 billion in Q3, driven by increased prescription volumes and demand for specialty products (Reuters).

The planned spin-off of the medical-surgical segment by H2 2027 is designed to allow a sharper focus on high-margin specialty and oncology drug distribution, which could unlock shareholder value (Reuters).

Fiscal 2027 profit guidance was only slightly above consensus, signaling limited upside compared to current market expectations (Reuters).

There is a risk of management disruption as CFO Britt Vitalone retires and Kenny Cheung assumes the role on May 29, 2026, which could impact financial oversight and the execution of strategy (Reuters).

The planned spin-off of the medical-surgical business involves execution challenges and initial costs, which could draw resources and attention away from McKesson’s primary distribution business (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

McKesson Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

McKesson Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

McKesson News

AllArticlesVideos

McKesson Q4 Earnings Call Highlights

MarketBeat·3 weeks ago

McKesson expects 2027 profit slightly above estimates on drug distribution strength

Reuters·4 weeks ago

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets

Business Wire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.